CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
The S&P/ASX 200 (INDEXASX: XJO) is expected to take a backwards step when the market opens on Friday. Over in the US, big tech stocks like Amazon and Apple have crushed earnings expectations.
The Avita Therapeutics Inc (ASX: AVH) share price was trading 10.53% lower today following an investor update to do with its BARDA partnership.
What a month it was for the S&P/ASX 200 (INDEXASX: XJO) and markets more broadly in June 2020, rallying again to cap off the strongest quarter for the ASX in over 20 years.
The S&P/ASX 200 (INDEXASX: XJO) is expected to open lower on Monday. Telstra (ASX:TLS) shares, AdBri Ltd (ASX:ABC) and CSL Limited (ASX:CSL) will be the ASX shares to watch.
The S&P/ASX 200 (INDEXASX: XJO) is expected to jump this morning, according to data from the Sydney Futures Exchange. Here’s everything you need to know.
CSL (ASX:CSL) has announced a US$450 million acquisition to the market, AMT-061.
The chief financial officer (CFO) of CSL (ASX:CSL) has left to join BHP (ASX:BHP).
CSL (ASX:CSL) has announced an acquisition to the market this morning. It’s called Vitaeris, a clinical-stage biotechnology company.
The S&P/ASX 200 (INDEXASX: XJO) is tipped to open slightly lower on Friday with the most popular Sydney Futures Exchange contract pointing to a 14-point decline from yesterday. Here’s what you need to know.
